ArticleJournal of clinical hypertension (Greenwich, Conn.)2014
Resistant hypertension and associated comorbidities in a veterans affairs population.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology.Journal of nephrology · 2019Guideline
- Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.Hypertension (Dallas, Tex. : 1979) · 2018Guideline
- Prevalence and clinical outcomes of patients with apparent treatment-resistant hypertension enrolled in Phase 2 cardiac rehabilitation.Journal of clinical hypertension (Greenwich, Conn.) · 2020Trial
- Comparative study of hypertension, diabetes, dementia and smoking in military veterans and non-veterans: a quantitative study using primary healthcare data.BMJ military health · 2026Article
- Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease.European heart journal · 2025Review
- Article
- Characteristics and Predictors of Apparent Treatment-Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data.American journal of hypertension · 2024Article
- The Global Burden of Resistant Hypertension and Potential Treatment Options.European cardiology · 2024Review
- Apparently Resistant Hypertension in Polish Hemodialyzed Population: Prevalence and Risk Factors.Journal of clinical medicine · 2023Article
- Systolic Blood Pressure and Pulse Pressure Are Predictors of Future Cardiovascular Events in Patients with True Resistant Hypertension.Diagnostics (Basel, Switzerland) · 2023Article
- A Better Way to Breathe: Combining Allergy and Pulmonary Care Into One Clinic.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2023Article
- Lobar intracerebral hemorrhage and risk of subsequent uncontrolled blood pressure.European stroke journal · 2022Article
- Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort study.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Article
- The Importance of Cardiorespiratory vs. Muscular Fitness in Reducing the Odds of Hypertension in War Veterans: A Population-Based Study.International journal of environmental research and public health · 2021Article
- Prevalence and prognosis of the 2018 vs 2008 AHA definitions of apparent treatment-resistant hypertension in high-risk hypertension patients.Journal of clinical hypertension (Greenwich, Conn.) · 2020Article
- New Molecules for Treating Resistant Hypertension: a Clinical Perspective.Current hypertension reports · 2019Review
- Prevalence of Apparent Treatment-Resistant Hypertension in the United States.Hypertension (Dallas, Tex. : 1979) · 2019Article
- Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice.International journal of hypertension · 2019Article
- Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension.Kidney international · 2015Article
- Resistant hypertension: do all definitions describe the same patients?Journal of human hypertension · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistant hypertension (RH) is understudied and its reported prevalence varies with study populations. The authors sought to determine its prevalence and association with certain comorbid conditions in a Veterans Affairs population. This cross-sectional study utilized demographic and clinical data from 17,466 patients. Chi-square or t test was used for comparing groups with and without RH. Multivariate logistic regression analysis was used to determine independent associations. Overall, the prevalence of RH was 9%, and 13% of all hypertensive patients met criteria for RH. After adjusting for confounding variables, RH was significantly associated with older age (odds ratio [OR], 1.007), higher body mass index (OR, 1.04), Framingham score (OR, 1.14), and coexisting coronary artery disease, cerebrovascular accident/transient ischemic attack, peripheral vascular disease, congestive heart failure, chronic kidney disease, diabetes mellitus, erectile dysfunction, and metabolic syndrome (OR, 1.3, 1.32, 1.29, 2.88, 2.13, 1.2, 1.12, and 1.2, respectively; all P<.05). Our results indicate a complex interplay of certain comorbid conditions among patients with RH and suggest the need for multifaceted interventions in this high-risk population to prevent cardiovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.